#clinical trial

The first studies, launched on July 31, will focus on viral persistence and cognitive dysfunction.

The device may be approved for clinical use within the next three years.

An FDA advisory committee expressed concerns about the safety of the fatty liver disease treatment.

VK2809 and pegozafermin are among several medications coming through the pipeline for fatty liver disease

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.

Black people make up only 6% and Latino people make up 5% of participants in cirrhosis trials in the United States.

A study found that only 43% of clinical trials reported race and ethnicity. The FDA issued guidance to address these inequalities.

“Over 40% of the vulnerable population in the U.S. lives within 5 miles of a CVS Pharmacy location, so we have a chance to engage them.”

Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.

The drugs naltrexone and bupropion are currently approved for other indications.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

New Yorker Alejandrina Peña had hepatitis C—until a great doctor and powerful new treatment gave her a fresh start.

The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.